Revenue
$2.23B
Gross Margin
-13.9%
Operating Margin
-153.3%
Net Margin
-143.6%
Income statement waterfall for Moderna (MRNA) — TTM through Q1 2026
Net income: −$3.19B
Margin breakdown for Moderna (MRNA) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $2.23B | $2.23B |
| Cost of Revenue | −$2.53B | −$309.00M |
| Gross Profit | −$309.00M | −$309.00M |
| Operating Expenses | −$3.10B | −$3.41B |
| Operating Income | −$3.41B | −$3.41B |
| Other Income / Expense | $274.00M | −$3.14B |
| Pre-tax Income | −$3.14B | −$3.14B |
| Income Tax | −$56.00M | −$3.19B |
| Net Loss | −$3.19B | −$3.19B |
- Revenue$2.23B
- Cost of Revenue−$2.53B
- Gross Profit−$309.00M
- Operating Expenses−$3.10B
- Operating Income−$3.41B
- Other Income / Expense$274.00M
- Pre-tax Income−$3.14B
- Income Tax−$56.00M
- Net Loss−$3.19B
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement